Discover
Derms and Conditions
Derms and Conditions
Author: Dermsquared
Subscribed: 46Played: 1,736Subscribe
Share
© 2025 Dermsquared
Description
Hear from the leading dermatologists and experts as they discuss the hottest topics in dermatology. Tune in for clinical practice tips and treatment pearls you can implement quickly and efficiently into your busy practices!
172 Episodes
Reverse
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Tina Bhutani, MD, to discuss the role of interleukin (IL)-23 inhibitors in managing moderate to severe psoriasis. They examine how IL-23 inhibitors compare with other biologic classes, particularly IL-17 inhibitors, and explore considerations for treatment selection in patients with psoriatic arthritis (PsA) and other comorbidities.
Dr Bhutani begins by reviewing the targeted mechanism of IL-23 inhibition and the efficacy and safety profiles of available agents. She compares IL-23 and IL-17 inhibition in patients with peripheral versus axial PsA, highlighting differences in the available evidence and the importance of considering coexisting conditions, particularly inflammatory bowel disease, when selecting treatment.
The discussion then turns to long-term disease management, including the durability of response associated with IL-23 inhibitors. Dr Bhutani highlights tildrakizumab and recent consensus recommendations addressing its use in older and medically complex patients. She considers how health care professional administration and every 12-weeks maintenance dosing may support treatment adherence, along with potential access advantages for Medicare beneficiaries.
Drs Del Rosso and Bhutani also examine the prevalence of metabolic syndrome among patients with psoriasis and its implications for biologic selection. They discuss how body mass index, cardiovascular and metabolic comorbidities, and differences in safety profiles may influence treatment decisions. Dr Bhutani concludes by emphasizing the importance of recognizing undertreated psoriasis and ensuring that eligible patients have access to effective systemic therapies.
Tune in to the episode for a discussion of IL-23 inhibitors in contemporary psoriasis management, including long-term efficacy, treatment adherence, and considerations for patients with complex medical histories.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, examines the pathophysiology of acne vulgaris, tracing how advances in our understanding of the disease have shaped treatment approaches. He reviews the four key components of acne development—sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and inflammation—with particular attention to the role of androgens in initiating the cascade of events that leads to acne lesion formation.
Dr Del Rosso begins with a historical perspective on acne management, discussing how early treatment strategies focused primarily on reducing bacterial proliferation and follicular hyperkeratinization. He revisits the introduction of benzoyl peroxide, topical retinoids, and antibiotics, highlighting how subsequent research revealed additional mechanisms of action, including the direct anti-inflammatory properties of retinoids and tetracycline antibiotics.
The discussion then turns to the role of the skin as an endocrine organ and its ability to locally produce androgens from circulating precursors. Dr Del Rosso explains how androgen receptor activation stimulates sebaceous gland activity, contributing to increased sebum production and creating conditions that favor Cutibacterium acnes proliferation and inflammation. Importantly, these processes can occur even in patients with normal circulating androgen levels.
Building on these mechanisms, Dr Del Rosso considers how available therapies address different components of acne pathophysiology. He discusses the introduction of topical clascoterone, an androgen receptor inhibitor, as an opportunity to target the sebum-related component of acne development alongside established topical therapies. He also reviews the distinct role of oral isotretinoin and its effects across multiple pathogenic pathways.
Tune in to the episode for a closer look at how the interconnected mechanisms of acne development inform treatment selection, the rationale for combining therapies with complementary mechanisms of action, and how this understanding can support discussions with patients about their treatment regimens.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Vivian Shi, MD, to discuss the changing treatment landscape of hidradenitis suppurativa (HS), emerging therapeutic approaches, and the potential to transform long-term outcomes through earlier intervention.
Reflecting on what she describes as a renaissance in HS care, Dr Shi discusses how the field has progressed from limited treatment options to an expanding therapeutic arsenal. Unlike psoriasis and atopic dermatitis, HS can leave irreversible scarring and structural skin damage even after inflammation is controlled. Dr Shi envisions a future in which earlier, more effective treatment may prevent patients from developing tunnels and other permanent sequelae, fundamentally changing the course of the disease.
A central challenge, however, is recognizing when to intervene. Dr Shi advocates for reconsidering how moderate HS is defined, emphasizing that even a limited number of inflammatory lesions or a single tunnel may warrant escalation of therapy. She and Dr Del Rosso also examine the multiple barriers to timely care, from access to knowledgeable clinicians and specialists to medication approvals and surgical services.
Looking ahead, Dr Shi highlights several promising therapeutic developments, including sonelokimab, an investigational IL-17A/F-targeting nanobody, and povorcitinib, an oral JAK inhibitor. She also discusses the potential of B-cell–targeted approaches and the importance of understanding HS as a heterogeneous disease that may ultimately require more individualized treatment strategies.
Tune in to the episode to hear Dr Shi's perspective on the future of HS management, why redefining moderate disease could help clinicians identify opportunities for earlier intervention, and how an expanding therapeutic toolbox may bring the field closer to preventing irreversible disease progression.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes back Jason Hawkes, MD, MS, for the second installment of their discussion on the “cytokine soup” underlying inflammatory skin diseases. Building on their previous conversation about type 2 inflammation, they turn their attention to type 1 and type 3 inflammatory pathways, examining how these immune responses contribute to disease manifestations and influence therapeutic approaches.
Dr Hawkes begins by clarifying the terminology surrounding T-helper cell populations and broader inflammatory pathways, including the distinction between Th1, Th2, and Th17 responses and type 1, type 2, and type 3 inflammation. He explains how immune cells develop distinct inflammatory profiles and why understanding the signals that drive these responses is increasingly important as targeted therapies continue to expand.
The conversation then shifts to psoriasis, a prototypical type 3 inflammatory disease, and the complexities that arise when multiple inflammatory pathways contribute to a patient's clinical presentation. Dr Hawkes discusses how the immune mechanisms underlying plaque psoriasis may differ from those involved in psoriatic arthritis, helping explain why skin and joint responses to treatment do not always align. The clinicians also examine how differences in inflammatory pathways contribute to infection susceptibility in psoriasis and atopic dermatitis, as well as certain adverse effects associated with targeted therapies.
Finally, Drs Del Rosso and Hawkes explore the immunologic diversity of psoriasis, from classic plaque disease to guttate, pustular, erythrodermic, and paradoxical presentations. They discuss how a better understanding of the inflammatory mechanisms underlying these distinct phenotypes may help explain variations in clinical presentation and response to treatment, bringing dermatology closer to more individualized therapeutic decision-making.
Tune in to the episode for a clinically grounded discussion of inflammatory pathways, the relationship between immune signaling and disease manifestations, and why understanding the science behind targeted therapies can help dermatologists make sense of what they observe in everyday practice.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Scott Elman, MD, to examine whether laboratory monitoring requirements for systemic dermatologic therapies reflect current evidence. With some prescribing recommendations rooted in data from more than a decade ago, the clinicians discuss where routine testing remains warranted, where it may be unnecessary, and how dermatologists can balance patient safety with the burden of excessive monitoring.
Dr Elman begins by examining laboratory monitoring practices for atopic dermatitis therapies, highlighting important distinctions between biologics targeting IL-4, IL-13, and IL-31 and Janus kinase (JAK) inhibitors. While routine laboratory monitoring may offer limited clinical value for certain biologics, JAK inhibitors warrant a different approach given their safety profiles. He discusses the rationale for baseline screening and follow-up testing, while questioning the value of repeated testing in patients without changes in risk factors or exposure.
The conversation then shifts to psoriasis, where recommendations for tuberculosis and hepatitis screening have historically been influenced by experience with tumor necrosis factor inhibitors. Dr Elman highlights emerging evidence and recent guidance challenging the need for routine tuberculosis testing with IL-17 and IL-23 inhibitors. The clinicians also clarify the distinction between hepatitis screening and liver function testing, emphasizing the importance of evaluating risk according to therapeutic class rather than applying uniform monitoring requirements.
Beyond laboratory testing, Drs Del Rosso and Elman explore the value of interdisciplinary collaboration when managing patients with complex comorbidities, including inflammatory bowel disease. They discuss how coordination with other specialists can support treatment decisions without unnecessarily limiting therapeutic options.
Tune in to the episode for a practical discussion of evidence-based laboratory monitoring, the potential consequences of unnecessary testing, and how individualized assessment, appropriate co-management, and attention to overall patient health can inform systemic treatment decisions in dermatology.








